ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2129

The Diagnostic Utility Of Anterior Knee Pain and Pain With Activities In Identifying Knees With MRI-Detected Structural Damage In The Patellofemoral Joint: The Multicenter Osteoarthritis Study

Joshua J. Stefanik1, Tuhina Neogi2, Jingbo Niu2, Neil A. Segal3, Cora E. Lewis4, Michael C. Nevitt5, Frank Roemer6, Ali Guermazi7 and David T. Felson8, 1Clinical Epidemiology, Boston University, Boston, MA, 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 3Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, 4Preventive Medicine, University of Alabama, Birmingham, Birmingham, AL, 5Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, 6Klinikum Augsburg, Augsburg, Germany, 7Boston University, Boston, MA, 8Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis.

Session Type: Abstract Submissions (ACR)


Background/Purpose: It is widely thought that patellofemoral joint (PFJ) pathology, a source of symptoms in knee osteoarthritis (OA), can be identified using patient history and pain location but this has not been evaluated in an OA population where tibiofemoral joint (TFJ) OA is also frequent. Treatment for PFJ and TFJ disease may differ making the identification of PFJ disease clinically important. Using MRI to identify knees with isolated PFJ disease, we sought to determine the diagnostic utility of anterior knee pain (AKP) and pain with specific activities to identify knees with isolated PFJ structural damage.

Methods: The Multicenter Osteoarthritis Study (MOST) is a NIH-funded prospective cohort study of older adults with or at risk of knee OA. We used data from the 60-month visit, the first visit at which a knee pain map was obtained, limiting our sample to knees with pain, aching, or stiffness in the past year. Subjects identified painful areas around their knee on the knee pain map, which was used to define AKP. Maximal WOMAC pain score was used to classify pain with stairs and walking on level ground (its absence might rule in PFJ pathology) to test their utility in identifying isolated PFJ damage. On MRIs from the same study visit, cartilage damage and bone marrow lesions (BMLs) were semi-quantitatively scored using the Whole Organ Magnetic Resonance Imaging Score. Knees with isolated PFJ damage (full-thickness cartilage loss or a BML in the PFJ and without either full-thickness cartilage loss or BML in the TFJ), isolated TFJ damage, and no structural damage were included (i.e., those with damage in both compartments were excluded). We determined the sensitivity (Sn), specificity (Sp), positive and negative predictive values (PPV and NPV) for AKP, pain with stairs, absence of pain with walking, and the combination of AKP and pain with stairs in identifying isolated PFJ damage. In sensitivity analyses we assessed pain with stair climbing vs. descending separately.

Results: 407 knees met our inclusion criteria (of 1185 knees with MRI read at 60 months). Of these, 193 (47%) had isolated PFJ damage, while 214 (53%) had either no damage (102; 25%) or isolated TFJ damage (112; 28%). AKP or activity pain showed only moderate or low Sn or Sp and correspondingly low PPV and NPV for identifying isolated PFJ (see table). Absence of moderate pain with walking had the greatest Sn (93%) but poor Sp. The combination of AKP and pain with stairs had the greatest Sp (82%) and but had low Sn (29%). We found similar results with other definitions of structural damage, WOMAC pain, and pain with stair climbing vs. descending.

Conclusion: Location of and specific activity-related pain do not appear to highly discriminate underlying isolated PFJ pathology from isolated TFJ or lack of damage. Clinical exam parameters (e.g., localized tenderness on exam) may perform better in identifying isolated PFJ structural damage than patient-reported measures.

 

Diagnostic utility of clinical symptoms commonly thought to indicate PFJ involvement with isolated PFJ structural damage (comparing knees with isolated PFJ damage to knees with either isolated TJF damage or no damage)

 

Sensitivity

Specificity

PPV

NPV

Anterior knee pain

60%

53%

53%

59%

Pain with stairs    

(≥ minimal)

74%

33%

50%

58%

Pain with stairs    

(≥ moderate)

40%

 

70%

 

54%

 

56%

 

Absence of pain with walking

(≤ minimal)

58%

50%

48%

54%

Absence of pain with walking

(≤ moderate)

93%

13%

49%

68%

Anterior knee pain + pain with stairs 

(≥ minimal)

49%

64%

56%

58%

Anterior knee pain + pain with stairs  (≥ moderate)

29%

82%

60%

56%

             

 


 


Disclosure:

J. J. Stefanik,
None;

T. Neogi,
None;

J. Niu,
None;

N. A. Segal,
None;

C. E. Lewis,
None;

M. C. Nevitt,
None;

F. Roemer,
None;

A. Guermazi,

Boston Imaging Core Lab,

1,

Merck Serono,

5,

Sanofi-Aventis Pharmaceutical,

5,

TissueGene,

5;

D. T. Felson,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-diagnostic-utility-of-anterior-knee-pain-and-pain-with-activities-in-identifying-knees-with-mri-detected-structural-damage-in-the-patellofemoral-joint-the-multicenter-osteoarthritis-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology